Endofitomedika - Company finances
|
EUR
|
2023
From: 2023-01-10
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 17,028 | 14,045 | 13,610 |
| Profit before tax | 1,138 | 3,846 | 6,348 |
| Net profit | 1,138 | 3,653 | 5,967 |
| Equity | 1,139 | 4,792 | 8,759 |
| Liabilities | 0 | 193 | 381 |
| Non-current assets | 0 | 0 | 0 |
| Current assets | 1,139 | 4,985 | 9,140 |
| Total assets | 1,139 | 4,985 | 9,140 |
|
Taxes paid
|
|||
| STI taxes | 84 | 68 | 193 |
|
Financial indicators
|
|||
| Revenue change y/y | - | -17.5% | -3.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 99.9% | 73.3% | 65.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 99.9% | 76.2% | 68.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 6.7% | 26.0% | 43.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 6.7% | 27.4% | 46.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Endofitomedika - Social security debts
The company had no debts to Sodra
Endofitomedika - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Endofitomedika, MB (code 306215571) is a Small partnership engaged in Traditional, complementary and alternative medicine activities. In 2025, the company generated €13.6K in revenue, down 3.1% year on year and 20.1% below the 2023 level. Despite the softer revenue base, profitability strengthened materially. Net profit reached €6.0K in 2025, compared with €3.7K in 2024 and €1.1K in 2023, lifting the net profit margin to 43.8% from 26.0% in 2024 and 6.7% in 2023. The balance sheet also expanded steadily: total assets increased to €9.1K in 2025 from €5.0K in 2024 and €1.1K in 2023, while equity rose to €8.8K. Liabilities remained very low at €381, supporting a equity ratio of 95.8% and a debt-to-equity ratio of 0.04. Return on equity was 68.1% and return on assets 65.3% in 2025, reflecting strong earnings relative to the company’s asset base. Asset turnover stood at 1.49x, indicating efficient use of assets in generating revenue.